Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15370
UPID:
ELOB_HUMAN
Alternative names:
Elongin 18 kDa subunit; RNA polymerase II transcription factor SIII subunit B; SIII p18; Transcription elongation factor B polypeptide 2
Alternative UPACC:
Q15370; B7WPD3
Background:
Elongin-B, known for its role in transcription elongation, enhances RNA polymerase II's ability to transcribe past arresting sites. It forms a crucial part of the elongin BC complex, contributing to the regulation of pluripotency in embryonic stem cells. Additionally, Elongin-B is a core component of ECS E3 ubiquitin-protein ligase complexes, involved in the ubiquitination and degradation of target proteins, including the von Hippel-Lindau ubiquitination complex CBC(VHL).
Therapeutic significance:
Understanding the role of Elongin-B could open doors to potential therapeutic strategies.